Dexcom Grows Q1 Revenue 15% to $1.2B, Keeps FY26 Outlook Unchanged
Dexcom has reported Q1 revenues of $1.2 billion, a 15% year-over-year increase, and maintains its fiscal 2026 revenue outlook of $5.16 billion to $5.25 billion with a gross margin target of 63%–64%. US sales reached $832 million while international sales totaled $360 million, up 26% year-over-year, driven by market expansions in France and Canada.
1. Q1 Revenue Growth and FY26 Guidance
Dexcom reported Q1 revenues of $1.2 billion, up 15% year-over-year, and reaffirmed its fiscal 2026 revenue guidance at $5.16 billion to $5.25 billion with a gross profit margin forecast of 63%–64%. The company highlighted that margins tracked in line with its targets despite external uncertainties.
2. US and International Sales Breakdown
US segment sales reached $832 million in Q1, while international continuous glucose monitoring product sales totaled $360 million, reflecting a 26% annual increase. Notable growth was recorded in recently expanded markets such as France and Canada, underscoring Dexcom’s focus on global expansion.
3. Geopolitical and Industry Context
Dexcom cited geopolitical tensions affecting shipping routes and fuel costs, including disruptions through the Strait of Hormuz, as factors influencing its margin outlook. Similar medtech firms have also tempered full-year forecasts due to rising freight and raw material expenses.